<DOC>
	<DOCNO>NCT01453075</DOCNO>
	<brief_summary>The purpose study study effect valacyclovir patient hepatitis C antibody herpes simplex type-2 . Herpes simplex type 2 virus cause genital herpes . Some person genital herpes sore private area person symptom . Valacyclovir medication commonly use treat prevent outbreak genital herpes . This medication already approve Food Drug Administration treat genital herpes . Valacyclovir approve treat chronic hepatitis C. The study take 16 week . Participants assign take either study drug , valacyclovir , sugar pill look exactly like valacyclovir . The researcher person participate know medication receive . Study visit occur every two week take approximately 3-45 minute . All study visit occur G.V . Sonny Montgomery VA Medical Center .</brief_summary>
	<brief_title>Evaluating Three Grams Daily Valacyclovir Patients With Chronic Hepatitis C HSV-2 Infection ( Phase I )</brief_title>
	<detailed_description>Study randomize , double-blinded , placebo-controlled , Phase II clinical trial . Participants recruit attend regularly schedule clinic appointment Jackson VA Medical Center . Baseline Visit . Participants randomize 1:1 group 10 receive valacyclovir 1.5 gram orally twice daily match placebo . Enrolled participant complete 12 week assign therapy . At initial visit , participant complete short questionnaire detail past medical/social history relevant symptom . Venipuncture perform obtain sample laboratory test . The baseline de-identified serum sample obtain clinical lab store research-approved freezer space future confirmation Biokit HSV-2 rapid assay . Follow-up visit schedule two-week interval baseline . At visit , pill-count , compliance tolerability medication assess use short questionnaire . Venipuncture perform every four week ( i.e. , every follow-up visit ) provide sample test describe . Information study visit record chart PI Research Assistant ( RA ) enter encrypted database VA server . Laboratory Tests . HSV-2 infection confirm perform Biokit HSV-2 rapid assay baseline store serum sample use method previously describe proposal . Laboratory test include 1 ) complete blood count , comprehensive metabolic profile , quantitative hepatitis C virus ( HCV ) RNA ; 2 ) Focus HerpeSelect HSV-1 Immunoglobulin G ( IgG ) participant seronegative HSV-1 baseline . Patient 's IL28-B genotype also assess baseline . The PI review laboratory parameter . Baseline characteristic group compare use appropriate parametric test . Analysis intention treat inclusion subject randomize drug placebo . The primary outcome change HCV viral load treatment group compare placebo . Because investigator expect 0.5 log10 decline HCV viral load , investigator use one-sided parametric test . All viral load log10-transformed analysis .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Documentation chronic HCV infection genotype test previous positive HerpeSelect HSV2 IgG assay Antiherpes immunomodulatory therapy past 30 day HIV chronic hepatitis B infection Decompensated liver disease ( ascites , hepatic encephalopathy , coagulopathy , jaundice/icterus ) Creatinine clearance &lt; 50 ml/min . Female subject pregnant nursing Gastrointestinal disorder might result malabsorption valacyclovir History erythema multiforme major , thrombotic thrombocytopenia purpura hemolytic uremic syndrome Therapy hepatitis C previous 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>herpes simplex type 2</keyword>
	<keyword>veteran</keyword>
</DOC>